It is made available under a CC-BY-NC-ND 4.0 International license .

Disease-specific variant interpretation highlighted the genetic findings in 2325 Japanese patients with retinitis pigmentosa and allied diseases

- 3
- 4 Kensuke Goto,^{#1} Yoshito Koyanagi,^{#1,2,3} Masato Akiyama,^{2,4} Yusuke Murakami,² Masatoshi
- 5 Fukushima,² Kohta Fujiwara,² Hanae Iijima,⁵ Mitsuyo Yamaguchi,⁵ Mikiko Endo,⁵ Kazuki
- 6 Hashimoto,⁶ Masataka Ishizu,⁷ Toshiaki Hirakata,⁸ Kei Mizobuchi,⁹ Masakazu Takayama,¹⁰
- 7 Junya Ota,¹ Ai Fujita Sajiki,¹ Taro Kominami,¹ Hiroaki Ushida,¹ Kosuke Fujita,¹ Hiroki
- 8 Kaneko,¹ Shinji Ueno,^{1,11} Takaaki Hayashi,⁹ Chikashi Terao,³ Yoshihiro Hotta,¹⁰ Akira
- 9 Murakami,⁸ Kazuki Kuniyoshi,¹² Shunji Kusaka,¹² Yuko Wada,¹³ Toshiaki Abe,¹⁴ Toru
- 10 Nakazawa,⁶ Yasuhiro Ikeda,⁷ Yukihide Momozawa,⁵ Koh-Hei Sonoda,^{†2} Koji M.
- 11 Nishiguchi^{†1}
- 12 # These authors contributed equally to this manuscript.
- 13 [†]Correspondence to Koh-Hei Sonoda & Koji M. Nishiguchi
- 14
- 15 1. Department of Ophthalmology, Nagoya University Graduate School of Medicine,
- 16 Nagoya, Japan
- 17 2. Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu
- 18 University, Fukuoka, Japan
- 19 3. Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative
- 20 Medical Sciences, Kanagawa, Japan
- 4. Department of Ocular Pathology and Imaging Science, Graduate School of Medical
- 22 Sciences, Kyushu University, Fukuoka, Japan
- 23 5. Laboratory for Genotyping Development, RIKEN Center for Integrative Medical
- 24 Sciences, Kanagawa, Japan
- 25 6. Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai,
- 26 Japan
- 27 7. Department of Ophthalmology, Faculty of Medicine, University of Miyazaki, Miyazaki,
- 28 Japan
- 29 8. Department of Ophthalmology, Juntendo University Graduate School of Medicine,
- 30 Tokyo, Japan
- 31 9. Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan
- 32 10. Department of Ophthalmology, Hamamatsu University School of Medicine, Shizuoka,
- 33 Japan

- 34 11. Department of Ophthalmology, Hirosaki University Graduate School of Medicine,
- 35 Hisoraki, Japan
- 36 12. Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka-sayama,
- 37 Japan
- 38 13. Yuko Wada Eye Clinic, Sendai, Japan
- 39 14. Division of Clinical Cell Therapy, United Centers for Advanced Research and
- 40 Translational Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
- 41
- 42 *Correspondence:
- 43 Koji M. Nishiguchi
- 44 Department of Ophthalmology
- 45 Nagoya University Graduate School of Medicine
- 46 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8560, Japan
- 47 Tel: 81-52-744-2275; Fax: 81-52-744-2278
- 48 Email: kmn@med.nagoya-u.ac.jp
- 49
- 50 Koh-Hei Sonoda
- 51 Department of Ophthalmology
- 52 Graduate School of Medical Sciences, Kyushu University
- 53 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
- 54 Tel: 81-92-642-5648; Fax: 81-92-642-5663
- 55 E-mail: k.sonoda.a74@m.kyushu-u.ac.jp

It is made available under a CC-BY-NC-ND 4.0 International license .

56 Abstract

57 **Background:** As gene-specific therapy for inherited retinal dystrophy (IRD) advances,

- ⁵⁸ unified variant interpretation across institutes is becoming increasingly important. This
- 59 study aims to update the genetic findings of 86 retinitis pigmentosa (RP)-related genes in a
- 60 large number of Japanese RP patients by applying the standardized variant interpretation
- 61 guidelines for Japanese IRD patients (J-IRD-VI guidelines) built upon ACMG/AMP rules
- and assess the contribution of these genes in RP-allied diseases.
- 63

64 **Methods:** We assessed 2325 probands with RP (n=2155, including n=1204 sequenced

65 previously with the same sequencing panel) and allied diseases (n=170, all newly

analyzed), including Usher syndrome, Leber congenital amaurosis, and cone-rod dystrophy

- 67 (CRD). Target sequencing using a panel of 86 genes was performed. The variants were
- 68 interpreted according to the J-IRD-VI guidelines.
- 69

70 **Results:** A total of 3564 variants were detected, of which 524 variants were interpreted as

- 71 pathogenic or likely pathogenic. Among these 524 variants, 280 (53.4%) had been either
- 72 undetected or interpreted as variants of unknown significance or benign variants in our
- earlier study of 1204 RP patients. This led to a genetic diagnostic rate in 38.6% of RP

74 patients, with *EYS* accounting for 46.7% of the genetically solved patients, showing a 9%

75 increase in diagnostic rate from our earlier study. The genetic diagnostic rate for CRD

76 patients was 28.2%, with RP-related genes significantly contributing over other allied

- diseases.
- 78

79 **Conclusion:** A large-scale genetic analysis using the J-IRD-VI guidelines highlighted the

- 80 unique genetic findings for Japanese IRD patients; these findings serve as a foundation for
- 81 the clinical application of gene-specific therapies.

It is made available under a CC-BY-NC-ND 4.0 International license .

82 Introduction

- 83 Inherited retinal dystrophy (IRD) is a disorder characterized by the degeneration of photoreceptors and the retinal pigment epithelium, leading to symptoms such as night 84 blindness and visual impairment.¹⁻³ Retinitis pigmentosa (RP, OMIM 268000) is the most 85 86 common form of IRD, with a prevalence of approximately 1 in 3000–4000 people; thus, an estimated 2.5 million people worldwide have RP.¹⁴ Although effective treatments for IRD 87 have been limited in the past, recent advancements in gene/variant-specific therapies 88 suggest that IRD might now be amenable to interventions.⁵ Given the progress of genomic 89 90 medicine, there is a growing interest in the standardized interpretation of variants that can 91 be reproduced by different institutes. 92 Genetic screening studies for RP have reported variable diagnosis rates, in the range of 37.4% to 66.6% in Western countries⁶⁻⁹ and 29.6% to 72.1% in Asia.¹⁰⁻¹³ The rate may be 93 lower in Japan, ranging from 29.6% to 47.9%,^{10 14-16} depending on the report. The variation 94 95 in these figures could arise from whether the American College of Medical Genetics and 96 Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines¹⁷ were 97 applied for variant interpretation or how they were applied, as these guidelines require specification of multiple items that take into account the unique biological and 98 epidemiological characteristics of each inherited disease.¹⁸ Without predefined guidelines, 99 variant interpretation can differ substantially between institutes, which may contribute to 100 101 the variability in genetic interpretation of a given variant.¹⁹ Japan has a different genetic architecture of IRD compared to Western countries and even neighboring countries.^{14 20 21} 102 leading the Japanese Retina and Vitreous Society to publish a modified set of guidelines, 103
- 104 the Japanese inherited retinal dystrophy variant interpretation (J-IRD-VI) guidelines. These
- 105 guidelines are built upon predefined ACMG/AMP rules based on a thorough discussion
- among the expert members of key genetic laboratories and allow a uniform interpretation of
- 107 variants tailored specifically for Japanese patients.²²
- 108 In our previous collaborative genetic study using a next generation sequencing (NGS) panel
- 109 of 86 genes associated with RP, the rate of genetically solved cases (diagnosis rate) in 1204
- 110 RP patients was 29.6%.¹⁰ Unfortunately, the ACMG/AMP guidelines was not applied for
- 111 variant interpretation and a unique criteria was adopted, which relied heavily on the
- 112 interpretation of previous reports, without taking into consideration the quality of the
- 113 evidence provided in the literature. In addition, only typical RP phenotype was included in
- 114 the study, leaving out the genetic background of allied diseases, which are sometimes

- 115 difficult to differentiate from RP.
- 116 The purpose of this study was to update the genetic findings using the J-IRD-VI guidelines
- and expand our assessment to include a larger number of patients, especially those with a
- 118 phenotype that overlapped with RP. This study may serve as a foundation for future gene-
- 119 variant-specific therapies for IRD in Japan.

It is made available under a CC-BY-NC-ND 4.0 International license .

120 Materials and methods

121 Ethic statement and study subjects

- 122 This study was conducted in accordance with the principles of the Helsinki Declaration and
- 123 was approved by the ethical boards of each institute. All participants provided written
- 124 informed consent at their respective recruiting institute. An overview of the study is shown
- in figure 1. We collected DNA samples from 2662 patients with IRD from nine Japanese
- 126 facilities in the Japan Retinitis Pigmentosa Registry Project (2002–2021), namely Nagoya
- 127 University Hospital (n=790), Kyushu University Hospital (n=706), Tohoku University
- 128 Hospital (n=336), Yuko Wada Eye Clinic (n=327), Kindai University Hospital (n=203),
- 129 University of Miyazaki Hospital and Miyata Eye Hospital (n=112), Juntendo University
- 130 Hospital (n=87), The Jikei University Hospital (n=63), and Hamamatsu University Hospital
- 131 (n=38). When collecting DNA samples, each sample was assigned an anonymized number
- by each institute to ensure that the individual subjects cannot be identified by members
- 133 outside of each institute.
- 134

135 **Patient selection**

136 From a total of 2662 patients, we selected for analysis patients with RP and patients with

- 137 allied diseases with clinical findings that overlap with RP, including Usher syndrome,
- 138 Leber congenital amaurosis (LCA), cone-rod dystrophy (CRD), choroideremia, and Bietti
- 139 crystalline dystrophy (BCD). Clinical diagnoses were made by well-trained
- 140 ophthalmologists based on symptoms such as visual acuity loss, visual field loss,
- 141 photophobia and night blindness, fundus examination, electroretinogram, fundus
- 142 autofluorescence images, and optical coherence tomography images. We excluded patients
- 143 (n=258) with IRD with substantially different phenotypes from RP, including macular
- 144 dystrophy, Best disease, and Stargardt disease. We also excluded related patients (n=80) so
- 145 that a single patient represented each family. As a result, we enrolled 2325 probands with
- 146 non-syndromic RP (n=2155, including n=1204 we had previously sequenced with the same
- 147 sequencing panel¹⁰) or allied diseases (n=170), such as Usher syndrome (n=32), LCA

148 (n=15), CRD (n=78), choroideremia (n=11), or BCD (n=34).

149

150 **Target sequencing for 86 genes**

- 151 We used a previously established panel of 86 genes associated with RP and allied
- 152 diseases.¹⁰ These genes include 83 genes associated with RP that were registered in the

It is made available under a CC-BY-NC-ND 4.0 International license .

- 153 Retinal Information Network (RetNet) as of September 19, 2017, as well as three additional
- 154 genes (*CHM*, *CEP290*, and *IMPG1*) that are major causative genes for other IRDs. Our
- 155 study was designed to capture the coding regions of the transcripts as well as 2 bp into each
- 156 exon-adjacent intron and also include a deep intronic variant, c.2991+1655 A>G, in
- 157 CEP290. Multiplex polymerase chain reaction (PCR)–based target sequencing was
- 158 performed as described previously.²³ Briefly, multiplex PCR was performed by designing
- 159 primers covering all coding regions of the 86 genes. Next, a second PCR test was
- 160 performed to add dual barcodes to the first PCR product. Finally, the second PCR product
- 161 was sequenced using a HiSeq 2500 instrument (Illumina, San Diego, CA) to obtain 2×151
- 162 bp paired end reads with dual 8 bp barcode sequences.
- 163

164 Analysis of sequencing data

- Analysis of sequence data was performed as previous reported.¹⁰ Sequencing reads were
 demultiplexed using bcl2fastq2 V.2.20 (Illumina), followed by alignment to the human
- reference genome (hg19) using Burrows-Wheeler Aligner (V.0.7.17). Post-alignment
- 168 processing, including indel realignment, was performed with the Genome Analysis Toolkit
- 169 (GATK) (V.3.7), leading to variant calling via HaplotypeCaller and UnifiedGenotyper, and
- 170 subsequent integration of variants. Alternative allele frequencies (AF) were calculated
- using SAMtools (V.1.6) and genotype variants were selected based on frequency
- 172 histograms and quality filtering. The final set of identified variants was annotated using
- 173 ANNOVAR (V.3.4) and SnpEff (V.4.3), with the transcripts registered in CCDS Release 24
- and refGene. We defined the covered region as a region with bases having ≥ 20 sequencing
- reads in the target region. The coverage per base was calculated as the number of covered
- samples divided by the number of all samples. The cover rate per gene (%) was defined as
- 177 the average coverage per base of the target region. We successfully sequenced $\ge 98.0\%$ of
- the targeted regions of the 86 genes in all 2325 samples and used all samples for further
- analysis. The average read depth (\pm SD) was 1410 (\pm 359) per sample. We called variants in
- 180 the regions with \geq 20 read depth, which included 99.65% of the targeted regions (online
- 181 supplementary table S1). We confirmed the presence of pathogenic variants through visual
- 182 inspection using the integrative genomics viewer (IGV), making manual corrections for
- 183 annotations when multiple alternative alleles or single-nucleotide variants with deletions
- 184 were identified at the same site. This led to the reassignment of annotations for 10 variants
- across four genes (see online supplementary figure S1 and table S2).

It is made available under a CC-BY-NC-ND 4.0 International license .

186

187 Genotyping of the founder variants in *RP1* and *CYP4V2*

- In addition to NGS panel of 86 genes, we analyzed each of two variants associated with 188 IRDs²⁴⁻²⁶ in a different way, with *Alu* insertion in *RP1* and c.802-8 810del17insGC in 189
- CYP4V2; these genes are not detectable with our NGS panel. To screen Alu insertion in
- 190
- 191 exon 4 in *RP1* in all patients, we searched for *Alu* sequences in FASTQ files obtained by
- NGS using a grep search program, as previously reported.²⁷ We selected patients for whom 192 193 we had either detected Alu sequences in at least one read or who were heterozygous for
- 194 pathogenic variants in *RP1* as the subjects for genotyping. Genotyping was performed
- 195 using an optimized PCR-based method for the selected patients as previously described.²⁴
- 196 Among the subjects, 23 patients whose genotyping of Alu insertion was previously reported
- by us²⁴ were referenced for those results. To screen c.802-8 810del17insGC in CYP4V2 in 197
- 198 all patients, we developed a grep search program for FASTQ format files. We searched for
- 199 a unique 20-base sequence containing c.802-8 810del17insGC in CYP4V2 using the grep
- 200 command in Linux (online supplementary table S3), and the AF is calculated as (alternative
- 201 allele read count) / {(alternative allele read count) + (reference allele read count)} in all
- 202 patients. Allele frequencies ranging from 0.25 to 0.75 were defined as heterozygotes, while
- 203 frequencies ranging from 0.85 to 1.0 were defined as homozygotes.
- 204

205 Variant interpretation

- 206 Among the 86 genes in our NGS panel, two genes that had previously been reported as
- associated with RP but whose pathogenicity has been questioned by recent studies²⁸⁻³⁰ were 207
- excluded from our analysis, resulting in a final set of 84 genes for interpretation of 208
- 209 pathogenicity. We interpreted the variants according to the J-IRD-VI guidelines²² published
- 210 by the Japanese Retina and Vitreous Society. A detailed description of the evaluation
- 211 procedures is provided below. The automated application AutoPVS1
- (http://autopvs1.genetics.bgi.com/)³¹ (accessed on 16 August 2022) was used to evaluate 212
- 213 the PVS1 criteria for null variants. As defined in the ACMG guideline criteria for hearing
- 214 $10ss^{31}$, we defined exons containing null variants with an AF exceeding 0.3% in
- 215 the Genome Aggregation Database $(gnomAD)^{32}$ as lacking functional significance. For 23
- 216 null variants that output errors (as not "null variants") due to differences in the definition of
- 217 the coding region in AutoPVS1, the PVS1 criteria were evaluated manually. To assess the
- frequency of variants in general populations (BA1, BS1, PM2), we used the gnomAD total 218

It is made available under a CC-BY-NC-ND 4.0 International license .

- 219 population, the gnomAD population max, the Human Genetic Variation Database (HGVD), 220 and Tohoku Medical Megabank Organization (ToMMo) 8.3KJPN. If the highest AF in any 221 of the four databases met the cut-off value, the respective criteria were applied to variants. 222 BA1 was not applied based on an expert opinion for variants previously reported as being 223 pathogenic by multiple groups but meeting the BA1 cut-off value (online supplementary table S4).³³⁻³⁸ To calculate odds ratios for minor alleles in the PS4 criteria, ToMMo 38KJPN 224 225 for autosome and 14KJPN for chromosome X were used as ancestry-matched controls. To evaluate PM3, we counted the number of probands with heterozygous pathogenic variants 226 227 and those with homozygotes from both our subject patients and the prior literature listed in 228 the Human Genome Mutation Database Professional (HGMD Professional, 2022.2). The 229 strength of PM3 was assessed by summing the counts of these two sets of probands. In the computational evidence category (PP3, BP4, BP7), we employed predictive tools: 230 REVEL³⁹ for predicting the pathogenicity of missense variants and Splicing AI⁴⁰ for 231 232 predicting splice site changes. The PP5 criteria were evaluated based on ClinVar (accessed 233 on 20 August 2022). The BP2 criteria were applied to variants founded in cases with 234 homozygous pathogenic variants within the same gene.
- 235

236 Criteria for genetic diagnosis

237 We performed a genetic diagnosis using the variants regarded as "pathogenic" or "likely 238 pathogenic" by the J-IRD-VI guidelines, as well as the two founder variants, Alu insertion in *RP1* and c.802-8 810del17insGC in *CYP4V2*. We applied the genetic inheritance forms 239 240 defined in RetNet for each gene, following the classical Mendelian inheritance pattern and 241 attempted to determine the causative variant and make a genetic diagnosis in each case as 242 previously reported.¹⁰ If a gene was registered on RetNet in multiple inheritance forms, we 243 determined the genetic inheritance form of each variant based on the prior literature. 244 Furthermore, when a patient had pathogenic variants in multiple genes leading to a genetic 245 diagnosis, all the genes were listed as potential causative genes, rather than selecting just one. Finally, we regarded patients whose causative genes were determined as "solved" and 246

247 patients whose causative genes could not be determined as "unsolved".

It is made available under a CC-BY-NC-ND 4.0 International license .

248 **Results**

249 **Results of variants interpretations of 86 genes in 2325 patients**

- 250 The clinical characteristics of the patients are summarized in table 1. In the RP patients, the
- modes of inheritance as obtained from clinical records were as follows: AD in 284 (13.2%),
- 252 AR in 410 (19.0%), XL in 34 (1.6%) and sporadic in 1182 (54.8%) (table 1). A
- 253 comprehensive list of variant interpretation using J-IRD-VI guidelines is shown in online
- supplementary table S5. We identified a total of 3564 variants, including 2143 missense
- variants, 169 nonsense variants, 168 frameshift indels, 40 non-frameshift indels, 53
- canonical splice site variants, and 973 synonymous variants.
- 257 The detected variants were interpreted according to the J-IRD-VI guidelines using an in-
- house program. As a result, 211 variants were interpreted as pathogenic, 313 variants as
- likely pathogenic, 1880 variants as variants of unknown significance (VUS), 516 variants
- as likely benign, and 644 variants as benign. Among the 524 variants interpreted as
- 261 pathogenic or likely pathogenic, 209 (39.9%), 249 (47.5%), and 290 (55.3%) had not
- 262 previously been reported in our earlier study of 1204 patients with typical RP, HGMD, or
- 263 ClinVar, yielding 107 new disease-associated variants. This included 71 variants considered
- VUS or benign variants in the previous study. At the same time, 118 variants considered
- 265 pathogenic or likely pathogenic were reassigned to the VUS or benign categories. Thus,
- 266 only 245 out of 363 pathogenic or likely pathogenic variants (67.5%) in the previous study
- 267 maintained the same interpretation in the current study.
- 268

269 Genotyping results of *Alu* insertion in *RP1* and c.802-8 810del17insGC in *CYP4V2*

- 270 Two frequent variants in *RP1* and *CYP4V2* are known to be associated with RP and allied
- diseases and are missed by the standard analysis pipeline; thus, we analyzed them in a
- different way. To look for the known common 328bp *Alu* insertion [c.4052 4053ins328,
- 273 p.(Tyr1352Alafs)] in *RP1*,^{24 26} we conducted screening of FASTQ files using a grep search
- program²⁷ in all patients. *Alu* sequences were detected in at least one read for 24 patients.
- 275 Then, we selected a total of 138 patients for whom we either detected *Alu* sequences in at
- least one read or who were heterozygous for pathogenic variants in *RP1* as the subjects for
- 277 genotyping. These samples were further analyzed with a PCR-based method. We found that
- 278 24 patients were heterozygous for the *Alu* insertion and 10 were homozygous. Among the
- 279 24 patients who were heterozygous carriers of *Alu* insertions, 18 were found to have
- another pathogenic variant in *RP1*. As for the splice site variant c.802-8_810del17insGC in

It is made available under a CC-BY-NC-ND 4.0 International license .

281 *CYP4V2*, which is associated with BCD^{25} , we screened all patients by the searching for a

282 20-base sequence encompassing the variant region in FASTQ files using software. This

revealed that 22 patients, including 16 with RP and 5 with BCD, were heterozygous and 16,

including 13 with BCD, were homozygous for this change (online supplementary table S6).

Among the 22 patients who were heterozygous, 5 with BCD and 1 with RP were found to

have another pathogenic variant in *CYP4V2*.

287

High-frequency pathogenic variants in solved and unsolved patients with RP

289 Figure 2 summarizes the proportion of causative variants detected in the solved patients

- 290 with RP (n=831) and pathogenic or likely pathogenic variants detected in unsolved patients
- with RP (n=1324) (figure 2B). In particular, [p.(Ser1653fs), p.(Gly843Glu), and
- 292 p.(Tyr2935*) in EYS] and Alu insertion [p.(Tyr1352Alafs)] in RP1 were found in 27.2%
- 293 (226/831), 20.1% (167/831), 11.9% (99/831), and 2.9% (24/831) of solved patients,

accounting for 18.2%, 13.2%, 8.1%, and 2.3% of the total alleles of causative variants,

respectively (figure 2A). Among unsolved patients, 37.0% (490/1324) were found to carry

pathogenic or likely pathogenic variants. Specifically, [p.(Gly843Glu), p.(Ser1653fs), and

297 p.(Tyr2935*) in *EYS*] were detected in 7.3% (96/1324), 5.0% (66/1324), and 3.0%

298 (40/1324) of unsolved patients, accounting for 16.4%, 11.2%, and 6.8% of the total alleles

of pathogenic or likely pathogenic variants carried in unsolved patients, respectively (figure2B).

301

302 Genetic diagnosis with the detected pathogenic variants

303 The overall genetic diagnosis rate was 38.4% (892/2325) for RP and allied diseases (figure

304 3). The figure was 38.6% (831/2155) for RP, 25.0% (8/32) for Usher syndrome, 6.7%

305 (1/15) for LCA, 28.2% (22/78) for CRD, 63.6% (7/11) for choroideremia, and 67.6%

306 (23/34) for BCD. The results for causative genes and variants for a total of 2325 patients

are summarized in online supplementary table S7. Of note, we detected 15 patients with

308 pathogenic or likely pathogenic variants in two genes, including 14 patients with RP and

309 one patient with choroideremia (online supplementary table S8).

Among the typical RP patients, 831 were genetically diagnosed with 320 pathogenic or

311 likely pathogenic variants in 49 genes (figure 4A). Pathogenic variants in *EYS*, which has

312 previously been reported to be the major gene responsible for RP in the Japanese

population, explained RP in nearly half (388/831, 46.7%) of solved patients, followed by

- 314 USH2A (67/831, 8.1%), RHO with dominant inheritance (41/831, 4.9%), RP1 with
- recessive inheritance (36/831, 4.3%), and *RPGR* (34/831, 4.1%). The breakdown of solved
- cases by inheritance pattern based on clinical information was 47.2%, 43.9%, 33.6%, and
- 41.2% for AD, AR, sporadic, and XL, respectively. When separately analyzed by
- inheritance pattern of each gene reported in RetNet, EYS (388/605, 64.1%) and USH2A
- 319 (67/605, 11.1%) accounted for 75.2% of patients diagnosed with ARRP (figure 4B).
- 320 Meanwhile, three genes (*RHO*, *RP1*, and *PRPH2*) explained more than half of solved cases
- 321 with ADRP (91/164, 55.5%). In X-linked RP (XLRP), pathogenic variants in *RPGR* were
- found in the large majority of solved patients (n=34/50, 68.0%).
- In Usher syndrome, a total of eight of 32 patients (25.0%) were genetically diagnosed. Six
- 324 patients had pathogenic variants in USH2A and two patients had pathogenic variants in
- 325 *CLRN1*. In LCA, only one of 15 patients was genetically diagnosed, while no pathogenic
- variant was detected in the remaining 14 (93.3%) patients, consistent with a previous report
- 327 indicating little overlap between genes linked to RP and LCA in Japan.^{15 41} In CRD,
- 328 variants in *CRX*, *PRPH2*, and *RP1* were the most commonly linked to the disease, each
- accounting for 7.7%, 5.1%, and 5.1% of the disease, respectively. Of the 11 patients
- 330 diagnosed with choroideremia, pathogenic variants in *CHM* were detected in six patients
- 331 (54.5%). Variants in the *CYP4V2* gene explained 67.6% (23/34) of patients with BCD, and
- 332 c.802-8 810del17insGC was detected in 5 compound heterozygotes and 14 homozygotes.

It is made available under a CC-BY-NC-ND 4.0 International license .

333 Discussion

334 In this study, we performed target sequencing in 2155 patients with RP and an additional 335 170 patients with allied diseases. This is nearly double the number of RP patients as in our 336 previous study, although 1204 patients from the previous study were also included in the 337 present one.¹⁰ We interpreted the detected variants according to the J-IRD-VI guidelines 338 which is based upon specified ACMG/AMP rules and tailored explicitly for IRD in the Japanese population.²² Our results showed that the genetic diagnosis rate was 38.6% in the 339 RP patients, which is higher than the corresponding rate of 29.6% in our previous work,¹⁰ 340 341 which adopted a different variant interpretation pipeline. Our findings are supported by the 342 diagnostic contribution of 107 newly assigned variants not reported in ClinVar, HGMD, or 343 our previous work, which comprised 20.4% of all pathogenic or likely pathogenic variants detected in this study. In addition, extra genotyping of common Alu insertion in RP1 and a 344 345 splice site variant in CYP4V2, both missed by our automated NGS analysis, contributed to 346 the increased diagnosis rate.

- 347 Although 1204 patients examined in our previous work were also included in this study,
- only 67.5% of pathogenic or likely pathogenic variants had the same interpretation in the
- 349 earlier work and this one. This could largely be attributed to the difference in interpretation
- 350 criteria; the previous study adopted variant interpretation posted in ClinVar and HGMD. As
- a result, the rate of contribution of the most prevalent disease genes changed considerably.
- In particular, the proportion of *EYS* jumped from 30.9% to 46.7% in the current study,
- 353 which may be explained in part by the recent establishment of a very frequent variant
- 354 [p.(Gly843Glu) in *EYS*] as pathogenic.³⁶ Additionally, through a stringent application of J-
- 355 IRD-VI guidelines, nearly all variants in *RP1L1*, which was previously the fifth most
- 356 prevalent RP-related gene in Japan and accounted for 4.8% of all solved RP cases, were
- 357 excluded in this study due to the high AF in the general population as defined in the J-IRD-
- 358 VI guidelines. Consequently, the current study has greatly enhanced the understanding of
- 359 the genetic architecture of Japanese RP patients.
- 360 This study also found that 37.0% of the unsolved RP patients carried pathogenic or likely
- 361 pathogenic recessive variants in one of the 86 RP-related genes. The AF of many of these
- 362 variants was higher than would be expected in the general population. For example, the AF
- 363 of p.(Ser1653fs) was 2.49% in unsolved RP patients and is 0.43% in the general population.
- 364 This may indicate that some of these heterozygous variants play a role in the disease in
- 365 unsolved cases and that there is a yet-unidentified pathogenic recessive variant *in trans* that

It is made available under a CC-BY-NC-ND 4.0 International license .

366 escaped the NGS panel sequence and standard analysis pipeline. Indeed, in an earlier 367 analysis, we carried out a genome-wide association study of RP, which showed a peak in the EYS locus that surpassed genome-wide significance ($P = 3.79 \times 10^{-10}$) and for which no 368 corresponding exonic variant in EYS was linked,³⁶ indicating that there may be at least one 369 370 more undiscovered high-frequency variant in this gene. Furthermore, through long read 371 sequencing of 15 heterozygous carriers of an *EYS* pathogenic variant, we identified a large structural variant encompassing multiple exons in EYS in 2 cases (13.3%),⁴² suggesting the 372 presence of undiscovered structural variants. Nevertheless, a more complex non-Mendelian 373 inheritance factor may also complicate genetic diagnosis,⁴³⁻⁴⁵ although the degree of its 374 375 importance in the context of overall genetic diagnosis remains largely unknown. 376 This study reports genetic analysis results of IRD cases with phenotypic overlap with RP in a somewhat limited number of patients. We found a significant contribution of RP-related 377 378 genes in the genetic diagnosis rate of CRD (22 of 78 patients, 28.2%), although the figure 379 was smaller than for RP (38.6%). Unlike RP, variants in *CRX* were the most frequent causes 380 of CRD and EYS variants accounted for the disease in only 3.8% of cases. This was in 381 contrast to patients with BCD or choroideremia, both rarely diagnosed as RP, in which 382 variants in CYP4V2 and CHM, respectively, explained most patients. Meanwhile, we reached genetic diagnosis in only one of 15 patients with LCA, consistent with previous 383 reports indicating that genes causing RP and LCA are largely different in the Japanese 384 385 population.^{15 41} Nevertheless, these findings are important in the era of genomic medicine 386 because many emerging treatments for IRD are developed for each disease gene with less 387 emphasis on the clinical diagnosis itself; thus, understanding the phenotypic spectrum of 388 each disease gene is critical for the clinical application of these treatments. 389 There several limitations to this study. First, the J-IRD-VI guidelines used for variant 390 interpretation are customized for and validated in only Japanese IRD patients. For example, 391 mainly Japanese databases were designed to assess the rarity or enrichment of a variant in 392 question. This means that the same analysis pipeline may not be applicable to countries 393 outside Japan, even neighboring Asian countries. Nevertheless, since Japan consists of 394 islands geographically isolated from elsewhere, it is unavoidable that there will be unique 395 criteria for a sensitive and specific genetic diagnosis. Second, the RP-related genes 396 analyzed in the current study were selected based on those reported as causing non-397 syndromic RP in RetNet as of 2017. They are not updated, nor do they comprehensively 398 cover genes reported for phenotypically related diseases such as CRD or LCA;

- 399 nevertheless, important novel RP-associated genes have not been reported in Japanese since
- 400 2017. It is likely that adopting whole exome sequencing or whole genome sequencing
- 401 would lead to an increased diagnostic rate, particularly in non-RP cases. Lastly, the number
- 402 of non-RP cases analyzed was too small to reach any conclusions. Nevertheless, the data
- 403 are sufficient to determine that there is a significant overlap between genes in RP and CRD
- 404 and that observing this is rare in some genes but more frequent in other genes, such as CRX,
- 405 *PRPH2*, or *RP1*.
- 406 In conclusion, our study stringently applied IRD-specific ACMG/AMP rules intended to
- 407 unify the genetic diagnosis of the disease within Japan in a large number of patients with
- 408 RP and allied diseases. This allowed us to substantially update the genetic background of
- 409 Japanese RP patients by detecting many new disease-associated variants. The results may
- 410 serve as an important foundation for developing future gene- or variant-specific treatments.

It is made available under a CC-BY-NC-ND 4.0 International license .

411 **Declarations**

412 **Ethics approval**

- 413 This study was approved by the ethics committees of all the collaborating hospitals and was
- 414 conducted in accordance with the tenets of the Declaration of Helsinki on biomedical
- 415 research involving human subjects. Written informed consent was obtained from all
- 416 subjects prior to participation in the study.
- 417

418 **Patient consent for publication**

- 419 Not required.
- 420

421 Availability of data and materials

- 422 All data relevant to the study are included in the article or uploaded as supplementary
- 423 information.
- 424

425 **Competing interests**

- 426 KMN reports grants from JCR Pharmaceuticals Co., Ltd., Sysmex Inc., and Novartis
- 427 Pharma Co., Ltd., consulting fees from Sysmex Inc. and Novartis Pharma Co., Ltd., and
- 428 Lecture fees from Sysmex Inc., Novartis Pharma Co., Ltd. and Janssen Co., Ltd.. KMN has
- 429 patents related to gene therapy for retinitis pigmentosa. In addition, KMN is an advisory
- 430 board member of Sysmex Inc. and Novartis Pharma Co., Ltd..
- 431

432 Authors' contributions

- 433 KG, YK, MA, YI, K-HS, and KMN designed the study. KG, YK, MA, YMu, MF, KFujiw,
- 434 KH, MI, THi, KM, MT, JO, AFS, TK, HU, HK, SU, THa, YH, AM, KK, SK, YW, TA, TN,
- 435 YI, K-HS, and KMN collected the samples and clinical data. KG, YK, HI, MY, ME, KFujit,
- 436 CT, and YMo performed the experiments and analyzed the data. KG, YK, MA, YMo, K-
- 437 HS, and KMN contributed to the manuscript preparation and editing. All authors
- 438 contributed to study conception and design, data interpretation, and approved the final
- 439 manuscript.
- 440

441 Acknowledgements

- 442 The study was supported by the Japan Retinitis Pigmentosa Registry Project and grants
- 443 from Japan Agency for Medical Research and Development (23ek0109632 to YI,

- 444 23ym0126071h0002 and 23ek0109660h0001 to KMN), Japan Society for the Promotion of
- 445 Science (20K23005 and 22K16969 to YK, 22K09831 to SU, 21K09756 to THa, 22K09825
- to KK, and 23H03059 to KMN), Japanese Retinitis Pigmentosa Society (JRPS) Research
- 447 Grant to YK, and Takayanagi Retina Research Award to YK. We acknowledge the
- 448 Laboratory for Genotyping Development in RIKEN and the RIKEN-IMS Genome
- 449 Platform.

It is made available under a CC-BY-NC-ND 4.0 International license .

451 **References**

- 452 1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet* 2006;368(9549):1795 453 809.
- 454 2. Campochiaro PA, Mir TA. The mechanism of cone cell death in Retinitis Pigmentosa. *Prog*455 *Retin Eye Res* 2018;62:24-37.
- 3. Sancho-Pelluz J, Arango-Gonzalez B, Kustermann S, Romero FJ, van Veen T, Zrenner E,
 Ekström P, Paquet-Durand F. Photoreceptor cell death mechanisms in inherited retinal
 degeneration. *Mol Neurobiol* 2008;38(3):253-69.
- 4. Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A, Jr., Woo SJ, Kwon YJ. Molecular
 genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical
 perspectives. *Prog Retin Eye Res* 2018;63:107-31.
- 5. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci 462 O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, 463 464 Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan 465 VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. Efficacy and safety of 466 voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated 467 468 inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 469 2017;390(10097):849-60.
- 6. Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, Braun TA,
 Mullins RF, Scheetz TE, Sheffield VC, Tucker BA. Clinically Focused Molecular
 Investigation of 1000 Consecutive Families with Inherited Retinal Disease. *Ophthalmology* 2017;124(9):1314-31.
- 7. Colombo L, Maltese PE, Castori M, El Shamieh S, Zeitz C, Audo I, Zulian A, Marinelli
 C, Benedetti S, Costantini A, Bressan S, Percio M, Ferri P, Abeshi A, Bertelli M,
 Rossetti L. Molecular Epidemiology in 591 Italian Probands With Nonsyndromic
 Retinitis Pigmentosa and Usher Syndrome. *Invest Ophthalmol Vis Sci* 2021;62(2):13.
- 8. Goetz KE, Reeves MJ, Gagadam S, Blain D, Bender C, Lwin C, Naik A, Tumminia SJ,
 Hufnagel RB. Genetic testing for inherited eye conditions in over 6,000 individuals
 through the eyeGENE network. *Am J Med Genet C Semin Med Genet*2020;184(3):828-37.
- 482 9. Weisschuh N, Obermaier CD, Battke F, Bernd A, Kuehlewein L, Nasser F, Zobor D,

⁴⁵⁰

483		Zrenner E, Weber E, Wissinger B, Biskup S, Stingl K, Kohl S. Genetic architecture						
484		of inherited retinal degeneration in Germany: A large cohort study from a single						
485	diagnostic center over a 9-year period. Hum Mutat 2020;41(9):1514-27.							
107	10 17							

- 10. Koyanagi Y, Akiyama M, Nishiguchi KM, Momozawa Y, Kamatani Y, Takata S, Inai C,
 Iwasaki Y, Kumano M, Murakami Y, Omodaka K, Abe T, Komori S, Gao D, Hirakata
 T, Kurata K, Hosono K, Ueno S, Hotta Y, Murakami A, Terasaki H, Wada Y,
 Nakazawa T, Ishibashi T, Ikeda Y, Kubo M, Sonoda KH. Genetic characteristics of
 retinitis pigmentosa in 1204 Japanese patients. *J Med Genet* 2019;56(10):662-70.
- 491 11. Gao FJ, Li JK, Chen H, Hu FY, Zhang SH, Qi YH, Xu P, Wang DD, Wang LS, Chang Q,
 492 Zhang YJ, Liu W, Li W, Wang M, Chen F, Xu GZ, Wu JH. Genetic and Clinical
 493 Findings in a Large Cohort of Chinese Patients with Suspected Retinitis Pigmentosa.
 494 *Ophthalmology* 2019;126(11):1549-56.
- 495 12. Kim YJ, Kim YN, Yoon YH, Seo EJ, Seo GH, Keum C, Lee BH, Lee JY. Diverse Genetic
 496 Landscape of Suspected Retinitis Pigmentosa in a Large Korean Cohort. *Genes*497 (*Basel*) 2021;12(5)
- 498 13. Chen TC, Huang DS, Lin CW, Yang CH, Yang CM, Wang VY, Lin JW, Luo AC, Hu FR,
 499 Chen PL. Genetic characteristics and epidemiology of inherited retinal degeneration
 500 in Taiwan. *NPJ Genom Med* 2021;6(1):16.
- 14. Numa S, Oishi A, Higasa K, Oishi M, Miyata M, Hasegawa T, Ikeda HO, Otsuka Y,
 Matsuda F, Tsujikawa A. EYS is a major gene involved in retinitis pigmentosa in
 Japan: genetic landscapes revealed by stepwise genetic screening. *Sci Rep*2020;10(1):20770.
- 505 15. Suga A, Yoshitake K, Minematsu N, Tsunoda K, Fujinami K, Miyake Y, Kuniyoshi K, 506 Hayashi T, Mizobuchi K, Ueno S, Terasaki H, Kominami T, Nao IN, Mawatari G, Mizota A, Shinoda K, Kondo M, Kato K, Sekiryu T, Nakamura M, Kusuhara S, 507 508 Yamamoto H, Yamamoto S, Mochizuki K, Kondo H, Matsushita I, Kameya S, 509 Fukuchi T, Hatase T, Horiguchi M, Shimada Y, Tanikawa A, Yamamoto S, Miura G, 510 Ito N, Murakami A, Fujimaki T, Hotta Y, Tanaka K, Iwata T. Genetic characterization of 1210 Japanese pedigrees with inherited retinal diseases by whole-exome 511 512 sequencing. Hum Mutat 2022;43(12):2251-64.
- 16. Maeda A, Yoshida A, Kawai K, Arai Y, Akiba R, Inaba A, Takagi S, Fujiki R, Hirami Y,
 Kurimoto Y, Ohara O, Takahashi M. Development of a molecular diagnostic test for
 Retinitis Pigmentosa in the Japanese population. *Jpn J Ophthalmol* 2018;62(4):451-

It is made available under a CC-BY-NC-ND 4.0 International license .

516 57.

- 17. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon
 E, Spector E, Voelkerding K, Rehm HL. Standards and guidelines for the
 interpretation of sequence variants: a joint consensus recommendation of the
 American College of Medical Genetics and Genomics and the Association for
 Molecular Pathology. *Genet Med* 2015;17(5):405-24.
- 522 18. Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J,
 523 Chapin A, Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M,
 524 Booth KT, Azaiez H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou
 525 Tayoun AN. Expert specification of the ACMG/AMP variant interpretation
 526 guidelines for genetic hearing loss. *Hum Mutat* 2018;39(11):1593-613.
- 527 19. Britten-Jones AC, Gocuk SA, Goh KL, Huq A, Edwards TL, Ayton LN. The Diagnostic
 528 Yield of Next Generation Sequencing in Inherited Retinal Diseases: A Systematic
 529 Review and Meta-analysis. *Am J Ophthalmol* 2023;249:57-73.
- 20. Hosono K, Ishigami C, Takahashi M, Park DH, Hirami Y, Nakanishi H, Ueno S, Yokoi
 T, Hikoya A, Fujita T, Zhao Y, Nishina S, Shin JP, Kim IT, Yamamoto S, Azuma N,
 Terasaki H, Sato M, Kondo M, Minoshima S, Hotta Y. Two novel mutations in the
 EYS gene are possible major causes of autosomal recessive retinitis pigmentosa in
 the Japanese population. *PLoS One* 2012;7(2):e31036.
- 535 21. Iwanami M, Oshikawa M, Nishida T, Nakadomari S, Kato S. High prevalence of
 536 mutations in the EYS gene in Japanese patients with autosomal recessive retinitis
 537 pigmentosa. *Invest Ophthalmol Vis Sci* 2012;53(2):1033-40.
- 538 22. Fujinami KN, K. M.; Oishi, A.; Akiyama, M.; Ikeda, Y. Specification of Variant
 539 Interpretation Guidelines for Inherited Retinal Dystrophy in Japan. *Jxiv* 2023
- Momozawa Y, Akiyama M, Kamatani Y, Arakawa S, Yasuda M, Yoshida S, Oshima Y,
 Mori R, Tanaka K, Mori K, Inoue S, Terasaki H, Yasuma T, Honda S, Miki A, Inoue
 M, Fujisawa K, Takahashi K, Yasukawa T, Yanagi Y, Kadonosono K, Sonoda KH,
 Ishibashi T, Takahashi A, Kubo M. Low-frequency coding variants in CETP and CFB
 are associated with susceptibility of exudative age-related macular degeneration in
 the Japanese population. *Hum Mol Genet* 2016;25(22):5027-34.
- 24. Nishiguchi KM, Fujita K, Ikeda Y, Kunikata H, Koyanagi Y, Akiyama M, Abe T, Wada
 Y, Sonoda KH, Nakazawa T. A founder Alu insertion in RP1 gene in Japanese patients
 with retinitis pigmentosa. *Jpn J Ophthalmol* 2020;64(4):346-50.

- 549 25. Wada Y, Itabashi T, Sato H, Kawamura M, Tada A, Tamai M. Screening for mutations in
 550 CYP4V2 gene in Japanese patients with Bietti's crystalline corneoretinal dystrophy.
 551 Am J Ophthalmol 2005;139(5):894-9.
- 26. Nikopoulos K, Cisarova K, Quinodoz M, Koskiniemi-Kuendig H, Miyake N, Farinelli P,
 Rehman AU, Khan MI, Prunotto A, Akiyama M, Kamatani Y, Terao C, Miya F, Ikeda
 Y, Ueno S, Fuse N, Murakami A, Wada Y, Terasaki H, Sonoda KH, Ishibashi T, Kubo
 M, Cremers FPM, Kutalik Z, Matsumoto N, Nishiguchi KM, Nakazawa T, Rivolta C.
 A frequent variant in the Japanese population determines quasi-Mendelian
- inheritance of rare retinal ciliopathy. *Nat Commun* 2019;10(1):2884.
- 27. Won D, Hwang JY, Shim Y, Byeon SH, Lee J, Lee CS, Kim M, Lim HT, Choi JR, Lee
 ST, Han J. In Silico identification of a common mobile element insertion in exon 4 of
 RP1. *Sci Rep* 2021;11(1):13381.
- 28. de Bruijn SE, Fiorentino A, Ottaviani D, Fanucchi S, Melo US, Corral-Serrano JC, 561 562 Mulders T, Georgiou M, Rivolta C, Pontikos N, Arno G, Roberts L, Greenberg J, 563 Albert S, Gilissen C, Aben M, Rebello G, Mead S, Raymond FL, Corominas J, Smith 564 CEL, Kremer H, Downes S, Black GC, Webster AR, Inglehearn CF, van den Born LI, 565 Koenekoop RK, Michaelides M, Ramesar RS, Hoyng CB, Mundlos S, Mhlanga MM, Cremers FPM, Cheetham ME, Roosing S, Hardcastle AJ. Structural Variants Create 566 567 New Topological-Associated Domains and Ectopic Retinal Enhancer-Gene Contact 568 in Dominant Retinitis Pigmentosa. Am J Hum Genet 2020;107(5):802-14.
- 569 29. Jin ZB, Mandai M, Homma K, Ishigami C, Hirami Y, Nao IN, Takahashi M. Allelic copy
 570 number variation in FSCN2 detected using allele-specific genotyping and multiplex
 571 real-time PCRs. *Invest Ophthalmol Vis Sci* 2008;49(9):3799-805.
- 30. Zhang Q, Li S, Xiao X, Jia X, Guo X. The 208delG mutation in FSCN2 does not associate
 with retinal degeneration in Chinese individuals. *Invest Ophthalmol Vis Sci* 2007;48(2):530-3.
- 31. Xiang J, Peng J, Baxter S, Peng Z. AutoPVS1: An automatic classification tool for PVS1
 interpretation of null variants. *Hum Mutat* 2020;41(9):1488-98.
- 577 32. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria
 578 AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA,
 579 Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN,
 580 Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta
 581 N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso

It is made available under a CC-BY-NC-ND 4.0 International license .

582 GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, 583 Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, 584 Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, 585 586 McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, 587 Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, 588 Watkins HC, Wilson JG, Daly MJ, MacArthur DG. Analysis of protein-coding 589 genetic variation in 60,706 humans. Nature 2016;536(7616):285-91.

- 33. Zernant J, Collison FT, Lee W, Fishman GA, Noupuu K, Yuan B, Cai C, Lupski JR,
 Yannuzzi LA, Tsang SH, Allikmets R. Genetic and clinical analysis of ABCA4associated disease in African American patients. *Hum Mutat* 2014;35(10):1187-94.
- 34. Valverde D, Riveiro-Alvarez R, Bernal S, Jaakson K, Baiget M, Navarro R, Ayuso C.
 Microarray-based mutation analysis of the ABCA4 gene in Spanish patients with
 Stargardt disease: evidence of a prevalent mutated allele. *Mol Vis* 2006;12:902-8.
- 596 35. Lee W, Zernant J, Su PY, Nagasaki T, Tsang SH, Allikmets R. A genotype-phenotype
 597 correlation matrix for ABCA4 disease based on long-term prognostic outcomes. *JCI* 598 *Insight* 2022;7(2)
- 36. Nishiguchi KM, Miya F, Mori Y, Fujita K, Akiyama M, Kamatani T, Koyanagi Y, Sato
 K, Takigawa T, Ueno S, Tsugita M, Kunikata H, Cisarova K, Nishino J, Murakami A,
 Abe T, Momozawa Y, Terasaki H, Wada Y, Sonoda KH, Rivolta C, Tsunoda T,
 Tsujikawa M, Ikeda Y, Nakazawa T. A hypomorphic variant in EYS detected by
 genome-wide association study contributes toward retinitis pigmentosa. *Commun Biol* 2021;4(1):140.
- 37. Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, HughbanksWheaton D, Heckenlively JR, Daiger SP. Mutations in the inosine monophosphate
 dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant
 retinitis pigmentosa. *Hum Mol Genet* 2002;11(5):559-68.
- 38. Wang XT, Mion B, Aherne A, Engel PC. Molecular recruitment as a basis for negative
 dominant inheritance? propagation of misfolding in oligomers of IMPDH1, the
 mutated enzyme in the RP10 form of retinitis pigmentosa. *Biochim Biophys Acta*2011;1812(11):1472-6.
- 39. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A,
 Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs

It is made available under a CC-BY-NC-ND 4.0 International license .

615 WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O,

- 616 Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona
- 617 WJ, Foulkes WD, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ,
- 618 Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore
- AS, Sieh W. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare
 Missense Variants. *Am J Hum Genet* 2016;99(4):877-85.
- 40. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D,
 Li YI, Kosmicki JA, Arbelaez J, Cui W, Schwartz GB, Chow ED, Kanterakis E, Gao
 H, Kia A, Batzoglou S, Sanders SJ, Farh KK. Predicting Splicing from Primary
 Sequence with Deep Learning. *Cell* 2019;176(3):535-48.e24.
- 41. Hosono K, Nishina S, Yokoi T, Katagiri S, Saitsu H, Kurata K, Miyamichi D, Hikoya A,
 Mizobuchi K, Nakano T, Minoshima S, Fukami M, Kondo H, Sato M, Hayashi T,
 Azuma N, Hotta Y. Molecular Diagnosis of 34 Japanese Families with Leber
 Congenital Amaurosis Using Targeted Next Generation Sequencing. *Sci Rep*2018;8(1):8279.
- 42. Sano Y, Koyanagi Y, Wong JH, Murakami Y, Fujiwara K, Endo M, Aoi T, Hashimoto K,
 Nakazawa T, Wada Y, Ueno S, Gao D, Murakami A, Hotta Y, Ikeda Y, Nishiguchi
 KM, Momozawa Y, Sonoda KH, Akiyama M, Fujimoto A. Likely pathogenic
 structural variants in genetically unsolved patients with retinitis pigmentosa revealed
 by long-read sequencing. *J Med Genet* 2022;59(11):1133-38.
- 43. Khanna H, Davis EE, Murga-Zamalloa CA, Estrada-Cuzcano A, Lopez I, den Hollander
 AI, Zonneveld MN, Othman MI, Waseem N, Chakarova CF, Maubaret C, Diaz-Font
 A, MacDonald I, Muzny DM, Wheeler DA, Morgan M, Lewis LR, Logan CV, Tan
 PL, Beer MA, Inglehearn CF, Lewis RA, Jacobson SG, Bergmann C, Beales PL,
 Attié-Bitach T, Johnson CA, Otto EA, Bhattacharya SS, Hildebrandt F, Gibbs RA,
 Koenekoop RK, Swaroop A, Katsanis N. A common allele in RPGRIP1L is a
 modifier of retinal degeneration in ciliopathies. *Nat Genet* 2009;41(6):739-45.
- 44. Kajiwara K, Berson EL, Dryja TP. Digenic retinitis pigmentosa due to mutations at the
 unlinked peripherin/RDS and ROM1 loci. *Science* 1994;264(5165):1604-8.
- 45. Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, Scambler PJ,
 Davidson WS, Beales PL, Lupski JR. Triallelic inheritance in Bardet-Biedl syndrome,
 a Mendelian recessive disorder. *Science* 2001;293(5538):2256-9.

It is made available under a CC-BY-NC-ND 4.0 International license .

647 Figure, Table

Table 1. Characterisics of 2325 Patients with RP and allied diseases

Diagnosis	RP	Usher syndrome	LCA	CRD	Choroideremia	BCD
Patients, n	2155	32	15	78	11	34
Sex (Male/Female)	1020/1135	12/20	6/9	46/32	11/0	9/25
Age, years	54.2 (4-93)	45.5 (10-80)	25.3 (3-57)	55.4 (3-84)	48.5 (3-84)	55.8 (27-82)
Visual acuity (logMAR), n (%)						
≤ 0.5	1302 (60.4)	19 (59.4)	2 (13.3)	20 (25.6)	9 (81.8)	20 (58.8)
0.5 <, ≤ 1.3	381 (17.7)	2 (6.3)	4 (26.7)	38 (48.7)	1 (9.1)	7 (20.6)
> 1.3	391 (18.1)	9 (28.1)	8 (53.3)	18 (23.1)	1 (9.1)	6 (17.6)
Unknown	81 (3.8)	2 (6.3)	1 (6.7)	2 (2.6)	0 (0)	1 (2.9)
Inheritance form, n (%)						
AD	284 (13.2)	0 (0)	0 (0)	9 (11.5)	0 (0)	2 (5.9)
AR	410 (19.0)	12 (37.5)	6 (40)	8 (10.3)	0 (0)	12 (35.3)
X linked	34 (1.6)	0 (0)	0 (0)	0 (0)	6 (54.5)	0 (0)
Sporadic	1182 (54.8)	16 (50)	9 (60)	59 (75.6)	3 (27.3)	19 (55.9)
Unknown	245 (11.4)	4 (12.5)	0 (0)	2 (2.6)	2 (18.2)	1 (2.9)
Consanguinity of patients, n (%)	152 (7.1)	2 (6.3)	8 (53.3)	4 (5.1)	0 (0)	3 (8.8)

Visual acuity is derived from the right eye. The values of the decimal visual acuity were converted into the logarithm of the minimum angle of resolution (logMAR) units. The inheritance forms were determined based on clinical examination and interview. RP, retinitis pigmentosa; LCA, Leber congenital amaurosis; CRD, cone-rod dystrophy; BCD, Bietti crystalline dystrophy. AD, autosomal dominant; AR, autosomal recessive.



648 Figure 1. Japanese facilities collecting IRD patients and workflow overview in this study. (A) The proportion of 2662 IRD patients from 9 facilities across Japan and their geographical 649 distribution. (B) The workflow following DNA sample collection. Nagoya, Nagoya 650 651 University Hospital; Kyushu, Kyushu University Hospital; Tohoku, Tohoku University 652 Hospital; Kindai, Kindai University Hospital; Miyazaki, University of Miyazaki Hospital; 653 Juntendo, Juntendo University Hospital; Jikei, the Jikei University Hospital; Hamamatsu, 654 Hamamatsu University Hospital; IRD, inherited retinal dystrophy; JRPRP, Japan Retinitis 655 Pigmentosa Registry Project; NGS, next-generation sequencing; RP, retinitis pigmentosa; J-656 IRD-VI, Japanese inherited retinal dystrophy variant interpretation.





- (A) The proportion of causative variants detected in solved patients with RP. A total of 1485
- alleles of causative variants were detected in solved patients with RP. High-frequency
- variants detected with more than 30 alleles are highlighted in the blue area. (B) The
- 661 proportion of pathogenic or likely pathogenic variants carried in unsolved patients with RP.
- A total of 587 alleles of pathogenic or likely pathogenic variants were detected in unsolved
- patients with RP. High-frequency variants detected with more than 30 alleles are
- highlighted in the blue area. RP, retinitis pigmentosa.



- **Figure 3. Percentage of solved patients and proportion of causative genes.**
- 666 The pie chart displays the overall and disease-specific diagnostic rates along with the
- ⁶⁶⁷ proportion of disease-causing genes. The blue area represents the proportion of genetically
- solved patients whereas the grey area represents that of unsolved patients. RP, retinitis
- pigmentosa; LCA, Leber congenital amaurosis; CRD, cone-rod dystrophy; BCD, Bietti
- 670 crystalline dystrophy.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4. Proportion of causative genes in solved patients with RP.

(A) The proportion of causative genes in solved patients with RP. The blue area represents

- 673 the proportion of AR genes, the brown area represents AD genes, and the grey area
- ⁶⁷⁴ represents X-linked genes. The green area represents multiple causative genes. (B) The
- proportion of causative genes based on the inheritance pattern. The pie chart excludes 12
- patients in whom multiple causative genes with different inheritance patterns were detected.
- AD, autosomal dominant; AR, autosomal recessive; n, number of patients; RP, retinitis
- 678 pigmentosa.